ACE and fatty liver disease: While the clinical relevance of thiazide-induced metabolic derangements remains uncertain at this time, hypertensive individuals at risk for diabetes and those with known hepatic steatosis should opt for antihypertensive agents that are metabolically benign – i.e. ARB or ACE inhibitors – until this issue is clarified.